FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2466434241> ?p ?o ?g. }

• W2466434241 endingPage "691" @default.
• W2466434241 startingPage "691" @default.
• W2466434241 abstract "Treatment of oropharyngeal squamous cell carcinoma (OPSCC) presents unique challenges and can be associated with significant morbidity. Transoral robotic surgery (TORS) has emerged as a treatment modality for OPSCC, but data comparing outcomes between patients treated with TORS-based therapy and nonsurgical therapy are limited.To compare survival and gastrostomy prevalence between patients with OPSCC treated with TORS-based therapy and those treated with nonsurgical therapy.This retrospective matched-cohort study identified patients with OPSCC treated at the University of Washington and University of Minnesota tertiary care medical centers from January 1, 2005, to December 31, 2013. Each patient treated with TORS-based therapy was matched by stage with as many as 3 patients treated with nonsurgical therapy. Final follow-up was completed on April 1, 2015.Disease-free survival, overall survival, and gastrostomy tube prevalence.One hundred twenty-seven patients met the study criteria (113 men [89.0%]; 14 women [11.0%]; median [interquartile range] age, 57 [52-63] years); 39 patients who underwent TORS were matched to 88 patients who underwent nonsurgical therapy. Compared with the nonsurgical group, more patients had p16-positive tumors in the TORS group (30 of 31 [96.8%] vs 30 of 37 [81.1%] among patients with known p16 status). No statistically significant difference in survival between treatment groups was found in multivariable analysis (disease-free survival hazard ratio, 0.22; 95% CI, 0.04-1.36; P = .10). Patients who received TORS-based therapy had lower gastrostomy tube prevalence after treatment (13 of 39 [33.3%] vs 74 of 88 [84.1%]) for a univariable relative risk of 0.43 (95% CI, 0.27-0.67; P < .001) and a multivariable relative risk of 0.43 (95% CI, 0.27-0.68; P < .001). Gastrostomy prevalence decreased by time after treatment for both groups (TORS group: 3 of 34 [9%] at 3 months to 1 of 33 [3%] at 12 months; nonsurgical group: 37 of 82 [45%] at 3 months to 7 of 66 [11%] at 12 months).Patients undergoing TORS for OPSCC have statistically indistinguishable survival but lower gastrostomy prevalence compared with patients undergoing nonsurgical therapy for stage-matched OPSCC. TORS offers promise for improved swallowing function in patients with OPSCC." @default.
• W2466434241 created "2016-07-22" @default.
• W2466434241 creator A5002427473 @default.
• W2466434241 creator A5021991186 @default.
• W2466434241 creator A5023776047 @default.
• W2466434241 creator A5031469994 @default.
• W2466434241 creator A5033491530 @default.
• W2466434241 creator A5037029325 @default.
• W2466434241 creator A5045097402 @default.
• W2466434241 creator A5056343535 @default.
• W2466434241 creator A5079431946 @default.
• W2466434241 date "2016-07-01" @default.
• W2466434241 modified "2023-10-18" @default.
• W2466434241 title "Survival and Gastrostomy Prevalence in Patients With Oropharyngeal Cancer Treated With Transoral Robotic Surgery vs Chemoradiotherapy" @default.
• W2466434241 cites W1526699258 @default.
• W2466434241 cites W1564950817 @default.
• W2466434241 cites W1912380597 @default.
• W2466434241 cites W1970558633 @default.
• W2466434241 cites W1994510965 @default.
• W2466434241 cites W1999821126 @default.
• W2466434241 cites W2000445173 @default.
• W2466434241 cites W2008527804 @default.
• W2466434241 cites W2022912114 @default.
• W2466434241 cites W2025111194 @default.
• W2466434241 cites W2039190237 @default.
• W2466434241 cites W2042065457 @default.
• W2466434241 cites W2043627607 @default.
• W2466434241 cites W2075893304 @default.
• W2466434241 cites W2077257970 @default.
• W2466434241 cites W2078433940 @default.
• W2466434241 cites W2089600839 @default.
• W2466434241 cites W2101792876 @default.
• W2466434241 cites W2107900756 @default.
• W2466434241 cites W2111442242 @default.
• W2466434241 cites W2113552973 @default.
• W2466434241 cites W2132239791 @default.
• W2466434241 cites W2144768747 @default.
• W2466434241 cites W2159510700 @default.
• W2466434241 cites W2162274983 @default.
• W2466434241 doi "https://doi.org/10.1001/jamaoto.2016.1106" @default.
• W2466434241 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6167603" @default.
• W2466434241 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27347780" @default.
• W2466434241 hasPublicationYear "2016" @default.
• W2466434241 type Work @default.
• W2466434241 sameAs 2466434241 @default.
• W2466434241 citedByCount "48" @default.
• W2466434241 countsByYear W24664342412016 @default.
• W2466434241 countsByYear W24664342412017 @default.
• W2466434241 countsByYear W24664342412018 @default.
• W2466434241 countsByYear W24664342412019 @default.
• W2466434241 countsByYear W24664342412020 @default.
• W2466434241 countsByYear W24664342412021 @default.
• W2466434241 countsByYear W24664342412022 @default.
• W2466434241 countsByYear W24664342412023 @default.
• W2466434241 crossrefType "journal-article" @default.
• W2466434241 hasAuthorship W2466434241A5002427473 @default.
• W2466434241 hasAuthorship W2466434241A5021991186 @default.
• W2466434241 hasAuthorship W2466434241A5023776047 @default.
• W2466434241 hasAuthorship W2466434241A5031469994 @default.
• W2466434241 hasAuthorship W2466434241A5033491530 @default.
• W2466434241 hasAuthorship W2466434241A5037029325 @default.
• W2466434241 hasAuthorship W2466434241A5045097402 @default.
• W2466434241 hasAuthorship W2466434241A5056343535 @default.
• W2466434241 hasAuthorship W2466434241A5079431946 @default.
• W2466434241 hasBestOaLocation W24664342411 @default.
• W2466434241 hasConcept C119060515 @default.
• W2466434241 hasConcept C126322002 @default.
• W2466434241 hasConcept C141071460 @default.
• W2466434241 hasConcept C167135981 @default.
• W2466434241 hasConcept C207103383 @default.
• W2466434241 hasConcept C2776530083 @default.
• W2466434241 hasConcept C2777014482 @default.
• W2466434241 hasConcept C2778045676 @default.
• W2466434241 hasConcept C2778424827 @default.
• W2466434241 hasConcept C2908642260 @default.
• W2466434241 hasConcept C3017742122 @default.
• W2466434241 hasConcept C44249647 @default.
• W2466434241 hasConcept C509974204 @default.
• W2466434241 hasConcept C71924100 @default.
• W2466434241 hasConcept C72563966 @default.
• W2466434241 hasConceptScore W2466434241C119060515 @default.
• W2466434241 hasConceptScore W2466434241C126322002 @default.
• W2466434241 hasConceptScore W2466434241C141071460 @default.
• W2466434241 hasConceptScore W2466434241C167135981 @default.
• W2466434241 hasConceptScore W2466434241C207103383 @default.
• W2466434241 hasConceptScore W2466434241C2776530083 @default.
• W2466434241 hasConceptScore W2466434241C2777014482 @default.
• W2466434241 hasConceptScore W2466434241C2778045676 @default.
• W2466434241 hasConceptScore W2466434241C2778424827 @default.
• W2466434241 hasConceptScore W2466434241C2908642260 @default.
• W2466434241 hasConceptScore W2466434241C3017742122 @default.
• W2466434241 hasConceptScore W2466434241C44249647 @default.
• W2466434241 hasConceptScore W2466434241C509974204 @default.
• W2466434241 hasConceptScore W2466434241C71924100 @default.
• W2466434241 hasConceptScore W2466434241C72563966 @default.
• W2466434241 hasIssue "7" @default.
• W2466434241 hasLocation W24664342411 @default.
• W2466434241 hasLocation W24664342412 @default.

• next